7 results about "STREPTOCOCCAL INFECTIONS" patented technology

In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.

The technology proposed herein concerns a vaccine formulation comprising a) an antigen comprising an amino acid sequence having at least 90% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, and b) a buffer having a pH of 6 to 8 and comprising: a. aluminum hydroxide gel particles, and b. a buffer system comprising: i. 1-3 mM phosphate and 100-200 mM NaCl, or ii. 5-15 mM histidine and 200-400 mM sorbitol. The technology proposed herein further concerns a method of producing a vaccine formulation as well as a vaccine formulation for use in a method of reducing, preventing and / or treating a GBS infection.

The present disclosure provides methods and kits for detecting Group A Streptococcus in biological samples. More particularly, the present disclosure provides methods for enhancing the specificity and sensitivity of Group A Streptococcus immunoassays by including N-propionyl-D-glucosamine, 2-N-butanoyl-D-glucosamide, Bis-(2-(D-2-deoxy-glucosaminyl))-PEG3-amide, m-PEG4-glucosamine, m-PEG6-glucosamine, or m-PEG10-glucosamine. The methods and kits disclosed herein are thus useful for reliable and early diagnosis of streptococcal infections in a subject.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

The present invention relates to streptococcal vaccine formulations and their use in generating immunity against streptococcal infection.

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

The invention discloses a novel antibacterial peptide based on deep learning identification and application thereof, and relates to the technical field of biology.The identification method comprises the steps that high-throughput precise mining is conducted on South Ocean microorganism metagenome source antibacterial peptides through deep learning, 10 representative candidate antibacterial peptides cAMP are focused, and the molecular weight of the antibacterial peptide cAMP is increased; and two lead compounds which have low hemolytic activity and low cytotoxicity and act on streptococcus pyogenes infection are obtained by adopting a chemical synthesis strategy, namely antibacterial peptides Southernin 36 and Southernin 134 with novel structures. Detailed pharmacological studies including in-vitro bacteriostatic activity, cytotoxicity and hemolytic activity, mouse epidermis infection model antibacterial activity study, bacteriostatic mechanism analysis and the like are carried out, and the application of the compound in preparation of antibacterial drugs is also carried out. The two novel antibacterial peptides Southernin 36 and Southernin 134, which are obtained by the invention and are derived from Southern Ocean microbiome, have a relatively good industrial application prospect.